Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
Displaying: 36,593 trials in your specialties ()
View trials across your selected specialties

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Hereditary Thyroid Gland Medullary Carcinoma, Multiple Endocrine ...
View Full Trial
INTERVENTION

Drug: Sorafenib Tosylate

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Washington University School of Medicine, Saint Louis, Missouri, United States

Brief Summary

This phase II trial studies how well sorafenib tosylate works in treating patients with medullary thyroid cancer that has spread to other parts of the body (metastatic), spread to the tissue surrounding the thyroid (locally advanced), or has returned after a period of improvement (recurrent). Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID)

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Covid19
View Full Trial
INTERVENTION

Drug: Chloroquine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Fundacion Valle del Lili, Cali, Valle Del Cauca, Colombia

Brief Summary

The purpose of this study is to assess the efficacy and safety of chloroquine prophylaxis on the incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections in healthcare workers exposed to patients with confirmed Coronavirus Disease 2019 (COVID-19)

A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    COVID-19
View Full Trial
INTERVENTION

Drug: Nafamostat Mesilate

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

The primary objective of this study is to evaluate the efficacy of CKD-314 (Nafabelltan) compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale in hospitalized adult patients diagnosed with COVID-19 pneumonia

Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    Waldenstrom Macroglobulinemia
View Full Trial
INTERVENTION

Drug: Acalabrutinib, Drug: Bendamustine, Drug: Rituximab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Brief Summary

This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with Waldenstrom's Macroglobulinemia. Symptomatic, previously untreated patients will receive SOC bendamustine and rituximab for 6 28-day cycles. Bendamustine will be given intravenously at 90 mg/m2 on days 1 and 2 of each cycle. Rituximab will be given on day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures)). Concomitantly, partcipants will receive 100 mg of the investigational product, acalabrutinib, orally for 1 year (365 days) at 100 mg BID.

Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    Neoadjuvant Treatment, Mucosal Melanoma
View Full Trial
INTERVENTION

Drug: Lenvatinib, Pembrolizumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Beijing Cancer Hospital, Beijing, Beijing, China

Brief Summary

This study is a randomized ,single center clinical study which is designed to investigate whether combination of Pembrolizumab with Lenvatinib could improve pCR rate and consequent survival in resectable mucosal melanoma. All the eligible patients were assigned to receive Lenvatinib once a day (QD) for 6 weeks plus pembrolizumab on Day 1 of each 21-day cycle (Q3W) concurrently on days 1 and 22, followed by surgery and 18 cycles of Pembrolizumab 200mg q3w of adjuvant phase.

Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

  • Status
    Active, not recruiting
  • Phase
    Early Phase 1
  • Condition
    Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis
View Full Trial
INTERVENTION

Drug: Standard heparin dose, Drug: Real time heparin dose adjustment

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Utah, Salt Lake City, Utah, United States

Brief Summary

The purpose of this study is to determine if weight-based heparin infusions at a rate of 10 units/kg/hour are sufficient to maintain a target anti-Xa of 0.1-0.35 IU/mL for VTE prophylaxis in patients undergoing microvascular surgery. Additionally, a pilot protocol has been developed to titrate these heparin infusions to ensure patients have sufficient VTE prophylaxis. All patients will be enrolled in the observational arm of the study and receive anti-Xa level monitoring. Patients with out-of-range anti-Xa levels will cross over to the interventional arm of the study and receive real time heparin infusion dose adjustments per the pilot protocol. The primary outcome measured will be the percentage of patients with anti-Xa levels in the target range of 0.1-0.35 IU/mL while on a heparin infusion at 10 units/kg/hour.

Healthy Summer Learners

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Overweight and Obesity, Academic Acheivement
View Full Trial
INTERVENTION

Behavioral: Healthy Summer Learners, Behavioral: 21st Century Summer Learning Center

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of South Carolina, Columbia, South Carolina, United States

Brief Summary

Summer vacation represents a "window of vulnerability" where dramatic declines in both health and academics occur for elementary age children. Currently, there are no summer programs that incorporate curriculum addressing both unhealthy weight gains and academic achievement simultaneously. This work represents an important step towards addressing important public health goals - obesity and learning - through a comprehensive program delivered during a timeframe - summer vacation - where substantial and long-lasting negative effects occur.

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Salivary Gland Cancer
View Full Trial
INTERVENTION

Drug: Nivolumab, Drug: Ipilimumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

Brief Summary

The purpose of this study is to find out what effects, good and/or bad, treatment with two drugs called nivolumab and ipilimumab have on the participant and salivary cancer.

Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Non-Hodgkin's Lymphoma Follicular, Non-Hodgkin's Lympho...
View Full Trial
INTERVENTION

Drug: Induction Venetoclax, Drug: Maintenance Venetoclax

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

Brief Summary

Patients with high tumor burden, low grade follicular lymphoma that has never been treated, will receive venetoclax in combination with obinutuzumab and bendamustine. Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with follicular lymphoma. Venetoclax may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether adding venetoclax to obinutuzumab and bendamustine improves the response (the tumor shrinks or disappears) in patients with follicular lymphoma. As of 9/5/2018, a higher than expected incidence of tumor lysis syndrome (TLS) was experienced among patients receiving venetoclax, obinutuzumab and bendamustine on Cycle 1, Day 1 of treatment. TLS is caused by the fast breakdown of cancer cells. These patients developed an increase in some of their blood tests (uric acid, phosphorus, potassium and/or creatinine). They received a medication called rasburicase and continued with treatment. It is unclear if the TLS was due to the venetoclax or the standard treatment of obinutuzumab and bendamustine. For the remaining patients, venetoclax will start on Cycle 2, Day 1 (previously Cycle 1, Day 1).

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Multiple Sclerosis, Relapsing-Remitting
View Full Trial
INTERVENTION

Drug: Ocrelizumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of California Irvine, Irvine, California, United States

Brief Summary

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks. The optional shorter infusion substudy will evaluate the safety of a shorter infusion of ocrelizumab in a subgroup of participants with early stage RRMS enrolled in the main MA30143 study. Approximately 700 patients will be enrolled in the substudy, and will receive additional 600 mg ocrelizumab administered in a shorter time frame.